A Prospective Angiogenic Imaging Study With DCE-MRI and DCE-USI in Patients With Colorectal Cancer and Liver Metastases Receiving Sunitinib in Addition to 5-FU, Folinic Acid and Irinotecan (FOLFIRI) as 1st Line Therapy.
Latest Information Update: 09 Nov 2021
Price :
$35 *
At a glance
- Drugs Sunitinib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Cancer metastases; Colorectal cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 20 Sep 2010 Planned end date changed from 1 Oct 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 20 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Dec 2008 New trial record.